**Supplemental Table 1. Demographic representation in PROFILE**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Unsampled | Sampled |  |
| N | 462 | 119 | p-value |
| Age (IQR) | 72 (66-77) | 73 (67-78) | 0.821 |
| Male | 78.14% | 74.79% | 0.436 |
| Smoker | 67.61% | 75.63% | 0.091 |
| FVC %pred (SD) | 76.7 (19.6) | 82.7 (20.0) | 0.004 |
| DLCO %pred (SD) | 42.9 (15.7) | 48.7 (16.3) | 0.001 |
| White cell count (SD) | 8.9 (2.4) | 8.8 (2.2) | 0.863 |
| Disease progression | 50.42% | 51.66% | 0.829 |

*Non-normally distributed data presented as median and interquartile range (IQR) and assessed by Mann-Whitney, normally distributed data presented as mean and standard deviation (SD) and assessed by unpaired t-test. Numbers in groups assessed by chi-squared. Values in Age and Disease progression based on n=330, white cell count based on n=261, all other values based on n>550.*

**Supplemental Table 2. Fibrocyte value change over time.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | n | Fibrocyte | SD | p-value |
| Baseline | 51 | 6.64 | 5.77 |  |
| 6 month | 51 | 5.99 | 5.16 |  |
| difference | 51 | 0.65 | 0.75 | 0.38 |

*Paired t-test indicated no significant difference between baseline and 6 month values. Repeated measures ANOVA with Greenhouse-Geisser effect correction F (1,48) = 1.48; p=0.18.*

**Supplemental Table 3. IPF risk of 12 month mortality for increments of 5% in circulating fibrocytes: sensitivity analysis.**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | n | died | HR | 95%CI | p-value | weight | HR\* | 95%CI\* | p-value\* | weight\* |
| Moeller | 60 | 13 | 1.57 | (1.11-2.24) |  | 49.2 | 1.60 | (1.04-2.44) |  | 42.3 |
| PROFILE | 102 | 13 | 1.18 | (0.84-1.67) |  | 50.8 | 1.19 | (0.83-1.71) |  | 57.7 |
| Overall | 162 | 26 | 1.36 | (1.06-1.74) | 0.014 | 100.0 | 1.35 | (1.02-1.78) | 0.035 | 100.0 |

*\*Hazard ratio (HR) for 5% increments of circulating fibrocyte level adjusted for gender, age and percent predicted FVC. Heterogeneity in unadjusted model: Cochran’s Q 1.28 p=0.258; I2 21.8%; mH2 0.280; tau2 0.009. Heterogeneity in adjusted model: Cochran’s Q 1.06 p=0.303; I2 5.6%; mH2 0.060; tau2 0.002, n=158.*

**Supplemental Table 4. IPF risk of overall mortality for increments of 5% in circulating fibrocytes: additional adjustment.**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | n | died | HR | 95%CI | p-value | weight | HR\* | 95%CI\* | p-value\* | weight\* |
| Moeller | 60 | 16 | 1.52 | (1.20-1.93) |  | 30.2 | 1.30 | (0.83-2.04) |  | 16.0 |
| PROFILE | 102 | 38 | 1.20 | (1.02-1.40) |  | 69.8 | 1.20 | (0.99-1.46) |  | 84.0 |
| Overall | 162 | 54 | 1.29 | (1.13-1.47) | <0.001 | 100.0 | 1.22 | (1.02-1.46) | 0.032 | 100.0 |

*\*Hazard ratio (HR) for 5% increments of circulating fibrocyte level adjusted for gender, age, percent predicted FVC, prednisolone, immunosuppression in fixed-effects model. Heterogeneity in unadjusted model: Cochran’s Q 2.64 p=0.105; I2 62.1%; mH2 1.635; tau2 0.018. Heterogeneity in adjusted model: Cochran’s Q 0.09 p=0.759; I2 0%; mH2 0.0; tau2 0.0, n=158.*